免疫调节剂治疗的银屑病患者对BNT162b2疫苗的抗体反应。
Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.
作者信息
Pavlotsky Felix, Segal Zvi, Barzilai Aviv
机构信息
Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Israel.
出版信息
J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):24-28. doi: 10.1177/24755303211056059. Epub 2021 Nov 12.
BACKGROUND
Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.
OBJECTIVE
This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.
METHODS
BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls.
RESULTS
Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.
CONCLUSIONS
Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.
背景
关于接受免疫调节药物治疗的银屑病患者中抗新冠病毒疫苗疗效的数据稀缺。
目的
本研究旨在检测这些患者接种BNT162b2疫苗后抗体阳性反应率。
方法
接种BNT162b2疫苗且接受免疫调节剂治疗的银屑病患者在接种第二剂疫苗后，通过雅培Architect或贝克曼库尔特对其针对新冠病毒刺突蛋白S的IgG抗体进行血清学检测。水平≥1 S1单位/毫升（S/ml）和>150任意单位/毫升（AU/ml）分别被视为抗体阳性反应。根据患者特征进一步分析抗体水平，并与医护人员对照组进行比较。
结果
51例患者中有49例出现抗体阳性反应。总体而言，接受免疫调节药物治疗的患者抗体水平与对照组相似。
结论
在绝大多数情况下，接受免疫调节剂治疗的银屑病患者似乎对完整的BNT162b2疫苗接种产生阳性抗体反应。
Zotero 插件